To this end, we selected the PLX3397 drug (also known as pexidartinib), which is widely used for the blockade of microglia and tumor-associated macrophages through the inhibition of the colony stimulating factor 1 receptor (CSF1R; Figures S6A and S6B). Here, CSF1R is linked to neoplasm.